{"nctId":"NCT01898923","briefTitle":"Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers","startDateStruct":{"date":"2012-11-23","type":"ACTUAL"},"conditions":["Diabetic Foot"],"count":236,"armGroups":[{"label":"ON101 Cream","type":"EXPERIMENTAL","interventionNames":["Drug: ON101 Cream"]},{"label":"Aquacel® Hydrofiber® dressing","type":"OTHER","interventionNames":["Other: Aquacel® Hydrofiber® dressing"]}],"interventions":[{"name":"ON101 Cream","otherNames":["WH-1"]},{"name":"Aquacel® Hydrofiber® dressing","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n1. Has signed a written informed consent prior to the first study evaluation;\n2. Male or female is at least 20 and \\< 80 years of age;\n3. Diabetes mellitus (type 1 or 2) with an HbA1c \\< 12.0% measured during screening or within three months prior to randomization;\n4. An ankle brachial index on the target limb at least 0.8 measured during screening or within three months prior to randomization;\n5. The target ulcer must have the following characteristics:\n\n   * Grade 1 or 2 per Wagner Ulcer Classification System;\n   * No higher than the ankle;\n   * No active infected;\n   * A cross-sectional area of between 1 and 25 cm2 post-debridement;\n   * Present for at least 4 weeks before randomization;\n6. If female and of childbearing potential has a negative pregnancy test and is not breastfeeding at screening visit;\n7. Able and willing to attend the scheduled visits and comply with study procedures.\n\nExclusion Criteria:\n\n1. Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement;\n2. Acute Charcot's neuroarthropathy as determined by clinical and/or radiographic examination;\n3. Has undergone revascularization procedure aimed at increasing blood flow in the treatment target limb \\< 4 weeks prior to randomization;\n4. Poor nutritional status defined as an albumin \\< 2.5 g/dL;\n5. Aspartate Aminotransferase(AST, GOT) and/or Alanine Aminotransferase(ALT, GPT) \\>3 x the normal upper limit;\n6. Serum Creatinine \\>2 x the normal upper limit;\n7. Treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 4 weeks before randomization;\n8. Use of any investigational drug or therapy within the 4 weeks prior to randomization;\n9. A psychiatric condition (e.g., suicidal ideation), current or chronic alcohol or drug abuse problem, determined from the subject's medical history, which, in the opinion of the Investigator, may pose a threat to subject compliance;\n10. Judged by the investigator not to be suitable for the study for any other reason.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Complete Ulcer Closure","description":"The primary variable is the number of target ulcers healed in each group within 16 weeks. The primary efficacy outcome is the comparison of the incidence of complete healing of the target ulcer between the two treatment groups at the end of treatment.\n\nFor the purpose of this study a complete healing will be defined as complete epithelialization which is maintained with no drainage for at least 2 weeks and is confirmed by a blinded assessor.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"The Time of Healing Rate","description":"Time to complete ulcer healing, The time of the original healing will be taken as the time to healing.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Ulcer Area","description":"Percentage change in ulcer surface area from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-78","spread":"42.6"},{"groupId":"OG001","value":"-78","spread":"34.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36","spread":"32.9"},{"groupId":"OG001","value":"-38","spread":"29.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a 50% Reduction of Ulcer Surface Area","description":"Percentage of subjects with a 50% reduction of ulcer surface area","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Infection of the Target Ulcer","description":"Incidence of infection of the target ulcer","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":122},"commonTop":["Hyperuricaemia","Eczema","Peripheral swelling","Pyrexia","Cellulitis"]}}}